BBOT - BridgeBio Oncology Therapeutics Inc.
About BridgeBio Oncology Therapeutics Inc. (https://bbotx.com)
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Yong Ben | Chief Medical & Development Officer | 1974 | $770,955 USD |
| Pedro J. Beltran | Chief Executive Officer and Director | 1971 | $767,662 USD |
| Frank McCormick | Co-Founder, Non-Executive Director & Chair of the Advisory Board | 1950 | $65,000 USD |
| Neil Kumar | Executive Chairman | 1979 | $20,000 USD |
| Aaron Chan | Vice President of Legal | – | – |
| Bin Wang | Senior Vice President of Drug Discovery | – | – |
| Daniel Watson | Senior Vice President of Chemistry, Manufacturing & Controls | – | – |
| Idan Elmelech | Chief Operating Officer | 1993 | – |
| Marc Cobo | VP of Finance & Controller | 1981 | – |
| Rui Xu | Senior Vice President of Drug Discovery | – | – |